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Background
Isolated myeloid sarcoma (MS) is a rare extramedullary tumor mass composed of malig-
nant myeloid precursor cells without any evidence of leukemia in the peripheral blood 
and bone marrow. We describe the clinical characteristics and outcomes of patients diag-
nosed with isolated MS at our institution.
Methods
We retrospectively reviewed 9 of 497 acute myeloid leukemia (AML) patients (1.8%) with 
isolated MS. Isolated MS patients were divided into 2 groups according to the first-line 
treatment strategy: systemic treatment only (S) or local treatment with or without sys-
temic treatment (LS).
Results
The most common site of MS occurrence was the head and neck area (N=4, 44.4%), 
followed by the anterior mediastinum (N=2, 22.2%) and the gastrointestinal tract (N=2, 
22.2%). The tumors of 4 patients (44.4%) eventually evolved to AML, in a median time 
of 13.4 months (range, 2.4‒20.1 mo). The number of patients achieving complete re-
mission after first-line treatment was higher in the LS group (N=5, 83.3%) than in the 
S group (N=1, 33.3%) (P=0.226). All patients in the LS group survived, but those in the 
S group died (P=0.012).
Conclusion
Accurate and rapid diagnosis using various modalities and the early initiation of intensive 
combined treatment may be the optimal strategies to reduce the risk of isolated MS sub-
sequently evolving to AML. To fully understand the characteristics of isolated MS, a larger 
number of patients from a multinational study is necessary.
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INTRODUCTION
Myeloid sarcoma (MS), also known as granulocytic sarco-
ma or chloroma, is an extramedullary tumor mass composed 
of malignant myeloid precursor cells. MS is a rare type of 
myeloid neoplasm reported in 2.5–9.1% of patients with 
acute myeloid leukemia (AML). MS generally presents as 
the first manifestation of AML at the time of diagnosis or 
at the time of relapse or progression of AML [1]. Less com-
monly, myeloproliferative neoplasms or myelodysplastic 
syndrome can transform into MS. Isolated MS is a unique 
presentation characterized as “non-leukemic MS,” and is de-
fined as the presence of a myeloblastic tumor or infiltration 
into a single or in multiple extramedullary organs without 
any evidence of leukemia in peripheral blood (PB) or bone 
marrow (BM). The period between initial diagnosis of iso-
lated MS and development of AML varies from 0.5 to 24 
months (median 3–9 mo) [2].
Although modern histological techniques have improved, 
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Table 1. The clinical and laboratory characteristics of the patients 
with isolated MS.
Characteristics All patients (N=9)
Age
Years, median (range) 38 (24–69)
Gender, N (%)
Male/female 5 (55.6%)/4 (44.4%)
Primary involved site, N (%)
Head & neck 4 (44.4%)
Anterior mediastinum 2 (22.2%)
Gastrointestinal tract 2 (22.2%)
Bone 1 (11.1%)
Primary involved site, N (%)
Head & neck/others 4 (44.4%)/5 (55.6%)
Number of lesions, N (%)
Solitary/multiple 4 (44.4%)/5 (55.6%)
White blood cells, ×109/L, median (range) 7.89 (5.15–13.85)
Hemoglobin, g/L, median (range) 13.4 (9.3–15.5)
Platelet, ×109/L, median (range) 273.0 (202–438)
LDH level, N (%)
WNR/ANR 4 (44.4%)/5 (55.6%)
Cytogenetics, N (%)
Normal/abnormal/unknown 6 (66.7%)/0 (0%)/
3 (33.3%)
The first-line treatment, N (%)
Surgery only 1 (11.1%)
Surgery followed by chemotherapy 2 (22.2%)
Surgery followed by radiotherapy 1 (11.1%)
Chemotherapy only 3 (33.3%)
Concurrent chemoradiotherapy 1 (11.1%)
Radiotherapy followed by chemotherapy 1 (11.1%)
The first-line treatment, N (%)
Local treatment/systemic treatment 2 (22.2%)/7 (77.8%)
Chemotherapy regimen (N=7), N (%)
AID 7.3/MACOP-B 6 (85.7%)/1 (14.3%)
Radiotherapy dose, gray, median (range) 31.5 (30.0–70.0)
Response to first-line treatment, N (%)
CR/PR/NR 6 (66.7%)/
2 (22.2%)/1 (11.1%)
Evolve to AML, N (%)
No/yes 5 (55.6%)/4 (44.4%)
Survival, N (%)
Alive/death 6 (66.7%)/3 (33.3%)
Cause of death, infection, N (%) 3 (33.3%)
CR duration, mo, median (range) 3.6 (0.2–13.3)
PFS, mo, median (range) 13.4 (2.4–20.1)
OS, mo, median (range) 19.1 (2.1–86.1)
Abbreviations: ANR, above normal range; CR, complete re-
mission; LDH, lactate dehydrogenase; NR, no response; OS, 
overall survival; PFS, progression-free survival; PR, partial 
remission; WNR, within normal range.
difficulty in diagnosing MS has been frequently reported, 
and 46–75% of MS cases are initially misdiagnosed, most 
commonly as a malignant lymphoma or even as non-hema-
topoietic tumors. Because of the limitation of diagnosis by 
conventional light microscopy, the exact incidence of MS 
has not yet been determined [3]. Therefore, immunohisto-
chemical analysis is important for lineage definition and 
differential diagnosis.
Isolated MS can occur at any age of population from pedia-
tric to elderly patients. The most commonly involved sites 
are the gastrointestinal (GI) tract, skin, bone, soft tissue, 
and lymph nodes (LNs) [4, 5]. Its clinical presentation can 
vary depending on the site of involvement. Although various 
treatment modalities, including systemic chemotherapy, ra-
diotherapy, surgery, or even allogeneic hematopoietic stem 
cell transplantation (HSCT), have been employed in treating 
isolated MS, prospective studies to suggest a proper treatment 
strategy have not been conducted owing to the rarity of 
the disease. Additionally, the lack of information regarding 
associated genetic abnormalities deters both clinical manage-
ment and investigations into molecular mechanisms under-
lying isolated MS [6]; hence, therapeutic decisions have tradi-
tionally relied on retrospective studies, case reports, and 
small case series [7]. In this study, we described the clinical 
characteristics and treatment outcomes of 9 patients with 
isolated MS diagnosed at our institution.
MATERIALS AND METHODS
Patients
A total of 497 patients were diagnosed with AML at 
Severance Hospital, Yonsei University, from March 1994 
to November 2015. Nine of 497 patients (1.8%) with isolated 
MS who met the following 3 criteria were enrolled: patholog-
ically confirmed extramedullary MS, fewer than 5% BM 
blasts, and no history of AML. All patients’ electronic medical 
records were reviewed to investigate the clinical and patho-
logical presentations, including age, gender, past history, 
physical examination, laboratory studies, treatment, and 
outcomes. MS was diagnosed by conducting immunohisto-
chemical analysis of fixed, paraffin-embedded tissue sections. 
Immunohistochemical analysis was performed by applying 
antibodies against myeloperoxidase (MPO), lysozyme, leuko-
cyte common antigen (LCA), terminal-deoxy-nucleotidyl- 
transferase (TdT), CD3, CD4, CD30, CD43, CD56, CD68, 
CD79a, CD99, and B-cell lymphoma-2 (BCL-2). Cells were 
considered positive for each marker if the marker was ex-
pressed by at least 20% of the neoplastic cells. Following 
the histologic confirmation of MS, BM biopsy and aspirate 
with karyotype and gene rearrangement analysis were per-
formed to rule out other hematologic malignancies. Gene 
rearrangement analyses for RUNX1-RUNX1T1, CBFB- 
MYH11, and BCR/ABL were conducted using polymerase 
chain reaction (PCR). Fluorescence in situ hybridization 
(FISH) and other molecular studies were not routinely per-
formed at the time of histologic diagnosis of MS. Flow cyto-
metric analysis on BM cells was performed at the time of 
diagnosis of AML.
Complete remission (CR) for MS was defined as complete 
disappearance of all detectable clinical and radiographic evi-
dence of disease and disappearance of all disease-related 
symptoms. Partial remission (PR) was defined as a reduction 
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Table 2. The clinico-pathological characteristics of all patients.
Case Gender/Age
Symptom at 
diagnosis Primary involved site
Chromo-
some Gene
IHC markers 
on MS biopsies
AML immunophenotypic 
markers by flow 
cytometry on BM cells
1 M/24 Chest wall pain Anterior mediastinum NA NA MPO, Lysozyme
2 F/38 Abdominal pain Jejunum, parametrium, LN NA NA MPO, CD68
3 F/56 Gingival swelling 
 and pain
Gingiva NA NA MPO, LCA CD13 (+), CD33 (+), 
CD45 (+), Anti-MPO (+), 
TdT (-)
4 M/24 Right eye proptosis Right orbit, LN NK NA MPO, CD43, CD79a CD19 (+), CD13 (+), 
CD33 (+), CD45 (+), 
CD79a (+), Anti-MPO (+), 
TdT (±)
5 M/29 Chest discomfort Anterior mediastinum, LN, 
 diaphragm, pleura, 
 pericardium
NK Negative MPO, LCA, CD99 CD7 (+), CD13 (+), 
CD33 (+), CD34 (-), 
CD45 (+), CD56 (+), 
HLA-DR (-), Anti-MPO (+), 
TdT (-)
6 F/69 Epigastric pain Jejunum NK NA MPO, LCA, CD56, 
 CD68
7 F/60 Left jaw painful 
 mass
Left submandibular gland, 
 LN
NK Negative MPO, LCA, Bcl-2 CD13 (+), CD33 (+), 
CD45 (+), CD117 (+), 
HLA-DR (-), Anti-MPO (+), 
TdT (-)
8 M/34 Back pain, bilateral 
 leg weakness
L2 vertebral body NK NA MPO, LCA
9 M/48 Nasal obstruction Nasal cavity, nasopharynx,
 oropharynx, right tonsil
NK NA MPO, LCA, CD56
Abbreviations: Bcl-2, B-cell lymphoma 2; BM, bone marrow; CD, cluster of differentiation; IHC, immunohistochemistry; LCA, leukocyte 
common antigen; LN, lymph node; MPO, myeloperoxidase; NA, not available; NK, normal karyotype; TdT, terminal deoxynucleotidyl 
transferase.
equal or more than 50% of the sum of the products of the 
greatest diameters of bidimensionally measurable lesions. 
Overall survival (OS) was measured from diagnosis to death 
or the last follow-up. Progression-free survival (PFS) was 
measured from diagnosis until progression to AML.
Imaging analysis
All imaging was performed at the radiology department 
in our institution. Computed tomography (CT) was per-
formed in 8 patients, magnetic resonance imaging (MRI) 
in 2 patients, and 18fluorine-labeled glucose positron emission 
tomography (PET) scanning in 2 of the 9 patients. Three 
patients underwent imaging with multiple modalities. CT 
scans were obtained in the axial plane by using a helical 
CT scanner with 2.5-mm-thick sections after the intravenous 
administration of iodinated contrast material. MRI was per-
formed with a 1.5-T magnet (Signa Advantage; GE Heal-
thcare, Milwaukee, WI, USA).
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 
(IBM Corp., Armonk, NY, USA). Categorical variables be-
tween the 2 groups were compared using the 2-sided Fisher 
exact test, and continuous variables using the Mann–
Whitney U test. A P-value ＜0.05 was defined as statistically 
significant for all analyses.
RESULTS
The important clinical and laboratory characteristics of 
all patients at the time of their isolated MS diagnosis are 
shown in Table 1. The median age was 38 years (range, 
24–69 yr); 5 patients (55.6%) were men and 4 (44.4%) women. 
The primary involved sites of isolated MS could be classified 
into 4 groups as follows: head and neck (N=4, 44.4%), anterior 
mediastinum (N=2, 22.2%), gastrointestinal (GI) tract (N=2, 
22.2%), and bone (N=1, 11.1%). Cytogenetic analysis of BM 
cells, which were routinely performed at the time of MS 
diagnosis, revealed a normal karyotype (NK) in all evaluable 
patients.
The presenting symptoms, such as chest pain, abdominal 
pain, gingival swelling and pain, proptosis, painful mass, 
back pain, weakness in both legs, and progressive nasal ob-
struction, were mainly related to the primary involved site 
of disease. Immunohistochemical staining of myeloid origin 
cells showed variable expression of MPO, lysozyme, LCA, 
CD43, CD56, CD68, CD79a, CD99, and BCL-2. The im-
munophenotyping of BM cells revealed myeloid anti-
gen-associated profiles of AML (Table 2).
On both CT and MRI, most of the MS lesions (N=7, 77.8%) 
were shown as discrete solid masses with variable enhance-
ment. Primary gingival involvement was found in one case 
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Fig. 1. Computed tomography (CT) findings of 56-year-old woman with primary gingival involvement (A) and 48-year-old man with nasal cavity and
naso-oropharynx involvement by myeloid sarcoma (B, C). (A) Contrast-enhanced axial CT scan of the neck shows lytic destruction of the right side
alveolar bone. (B) Contrast-enhanced axial CT scan of the neck shows diffuse thickening of the nasal cavity. (C) 18Fluorine-labeled glucose axial PET
scan shows strong focal uptake by the same lesions seen on the CT scan.
Fig. 2. Computed tomography (CT) and magnetic resonance imaging (MRI) findings of a 24-year-old man with involvement of the right orbit by 
myeloid sarcoma who reported right eye proptosis. (A) Contrast-enhanced axial CT scan of the orbit shows a homogeneously enhancing soft tissue 
mass in the intra-conal and extra-conal spaces of the right orbit. (B) T1-weighted axial MRI scan of the orbit shows a right orbit mass iso-intense 
to the periorbital muscle. (C) T2-weighted axial MRI scan of the orbit shows a right orbit mass mildly hyper-intense to the periorbital muscle.
in which lytic destruction of alveolar bone was also noted 
on CT (Fig. 1). Isolated MS in the nasal cavity and naso-or-
opharynx tended to cause diffuse thickening rather than 
discrete masses on CT. The nasal cavity and naso-orophar-
yngeal lesions were iso-dense to muscle on CT (Fig. 1). On 
18fluorine-labeled glucose PET-CT scans, strong focal uptake 
was observed in the nasal cavity and naso-oropharynx (Fig. 
1). On MRI, both orbital and spinal lesions were documented 
as well-defined or ill-defined soft tissue masses (Fig. 2, 3). 
Compared to adjacent muscle, the orbital lesions seen on 
pre-contrast CT scans were not attenuated by iodinated con-
trast material. Compared with the periorbital muscle, the 
lesion also showed an iso-intense signal on T1-weighted 
imaging and mild hyper-intense signals on the T2-weighted 
imaging (Fig. 2). A spinal MS in the epidural and para-
vertebral area was iso-intense and hyper-intense to muscle 
on T1- and T2-weighted MRI, respectively (Fig. 3).
Various first-line treatments to induce remission, such 
as medical, surgical, radiological, or combined treatment, 
were administered to patients upon diagnosis of isolated MS. 
Two patients (22.2%) were treated with local treatment 
alone, such as surgery and/or radiotherapy, and 7 (77.8%) 
with systemic treatment. After the first-line treatment, 6 
patients (66.7%) achieved a CR, 2 (22.2%) achieved a PR, 
and 1 (11.1%) failed to respond. The median time from 
diagnosis to the first CR was 3.6 months (range, 0.2–13.3 
mo). The tumors of 4 patients (44.4%) eventually evolved 
to AML after a median time of 13.4 months (range, 2.4–20.1 
mo) from MS diagnosis (Table 3). Two patients who received 
local treatment alone have maintained their CR status with-
out recurrence of MS (Table 3).
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Fig. 3. Magnetic resonance imaging (MRI) findings of a 34-year-old man with involvement of the second lumbar vertebral body by myeloid sarcoma 
who reported back pain and bilateral leg weakness. (A) Sagittal T1-weighted MRI scan of the spine shows an epidural and paravertebral mass 
iso-intense to muscle at the second lumbar vertebra level. (B) Sagittal T2-weighted MRI scan of the spine shows an epidural and paravertebral mass 
iso-intense or mildly hyper-intense to muscle at the second lumbar vertebra level. (C) Axial T2-weighted MRI scan of the spine shows a 
heterogeneously enhancing epidural mass with enhancement similar to or greater than that of normal muscle. 
Table 3. The treatment outcomes and follow-up of all patients.
Case Gender/Age
First-
line
treatment
Response
to 
first-line 
treatment
Second-
line 
treatment
Response 
to 
second-
line 
treatment
Interim
follow-
up
status
Third-
line
treatment
Response
to third-line
treatment
Fourth-
line
treatment
Response
to fourth-
line
treatment
Evolve
to
 AML
Survival
Overall
survival
duration
(mo)
Progression
-free
duration
(mo)
Cause
of death
Cause of 
death
1 M/24 CTx NR RTx for 
 MS
CR Relapse
 of MS
CTx for 
 MS
NR - - No Death 　8.9 - Infection Acute 
 appendicitis 
 & septic 
 shock
2 F/38 Op & CTx
 & Allo- 
 HSCT
CR - - - - - - - No Alive 24.1 - - -
3 F/56 CTx CR CTx for 
 AML
CR First 
 relapse
 of AML
CTx for 
 AML
CR Second 
 relapse
 of AML
NR Yes Death 27.4 20.1 Infection Pneumonia
 & septic 
 shock
4 M/24 CCRTx PR CTx for 
 AML
CR - - - - - Yes Alive 11.5 11.5 - -
5 M/29 CTx PR RTx for 
 MS
PR Progress
 to AML
CTx for 
 AML
NR CTx for 
 AML
NR Yes Death 2.4 2.4 Infection Pneumonia
 & septic 
 shock
6 F/69 Op CR - - - - - - - No Alive 2.1 - - -
7 F/60 Op & CTx CR - - Transfer 
 to other 
 hospital
- - - - Yes Alive 19.1 15.4 - -
8 M/34 Op & RTx CR - - - - - - - No Alive 86.1 - - -
9 M/48 RTx & CTx CR - - - - - - - No Alive 6.3 - - -
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; CCRTx, concurrent 
chemoradiotherapy; CR, complete remission; CTx, chemotherapy; MS, myeloid sarcoma; NR, no response; Op, operation; PR, partial 
remission; RTx, radiotherapy.
The patients with isolated MS were divided into 2 groups 
according to the first-line treatment strategy: patients with 
tumors who received systemic treatment only (S group, N=3) 
those who received local treatment with or without systemic 
treatment (LS group, N=6). In the LS group, the median 
age tended to be greater than that in the S group (43 vs. 
29 yr, P=0.214). The male to female ratio was similar between 
the 2 groups. The number of patients belonging to the head 
and neck group of the primary involved site was higher 
in the LS group (N=3, 50%) than in the S group (N=1, 33.3%), 
although this difference was not significant (P=0.381). There 
was also no statistical difference in the number of lesions 
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Table 4. The clinical and laboratory characteristics of the patients divided into first-line treatment strategies.
Characteristics Systemic treatment only (N=3) Local treatment±systemic treatment (N=6) P
Age, median (range), yr 29 (24–56) 43 (24–69) 0.214
Gender, N (%)
Male/female 2 (66.7%)/1 (33.3%) 3 (50%)/3 (50%) 0.595
White blood cells, ×109/L, median (range) 5.99 (5.48–10.38) 8.44 (5.15–13.85) 0.548
Hemoglobin, g/L, median (range) 12.8 (12.4–14.8) 13.7 (9.3–15.5) 0.381
Platelet, ×109/L, median (range) 284 (273–430) 248 (202–438) 0.190
LDH level, N (%)
WNR/ANR 1 (33.3%)/2 (66.7%) 3 (50%)/3 (50%) 0.595
Primary involved site, N (%) 0.381
Head & neck 1 (33.3%) 3 (50%)
Anterior mediastinum 2 (66.7%) 0 (0%)
Gastrointestinal tract 0 (0%) 2 (33.3%)
Bone 0 (0%) 1 (16.7%)
Number of lesions, N (%)
Solitary/multiple 2 (66.7%)/1 (33.3%) 2 (33.3%)/4 (66.7%) 0.595
Cytogenetics, N (%)
Normal/not available 1 (33.3%)/2 (66.7%) 5 (83.3%)/1 (16.7%)
Chemotherapy regimen (N=7), N (%)
AID 7.3/MACOP-B 2 (66.7%)/1 (33.3%) 4 (100%)/0 (0%)
Radiotherapy dose, gray, median (range) – 31.5 (30–70)
Response to first-line treatment, N (%)
CR/non-CR 1 (33.3%)/2 (66.7%) 5 (83.3%)/1 (16.7%) 0.226
Evolve to AML, N (%)
No/yes 1 (33.3%)/2 (66.7%) 4 (66.7%)/2 (33.3%) 0.524
Survival, N (%)
Alive/death 0 (0%)/3 (100%) 6 (100%)/0 (0%) 0.012
Cause of death, infection, N (%) 3 (100%) –
Diagnosis to CR duration, mo, median (range) 5.3 (3.4–7.3) 3.6 (0.2–13.3)
PFS, mo, median (range) 2.6 (2.4–20.1) 13.4 (11.4–15.4)
OS, mo, median (range) 8.9 (6.1–44.1) 21.5 (2.1–86.1)
Abbreviations: ANR, above normal range; CR, complete remission; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free 
survival; WNR, within normal range.
between the 2 groups (P=0.595). After first-line treatment, 
the number of patients who achieved a CR was higher in 
the LS group (N=5, 83.3%) than in the S group (N=1, 33.3%) 
(P=0.226). The number of patients who evolved to AML 
was higher in the S group (N=2, 66.7%) than in the LS 
group (N=2, 33.3%) (P=0.524). On follow-up, all patients 
in the LS group survived, but those in the S group died 
(P=0.012) (Table 4). Because of the small number of patients 
in our study, meaningful results could not be obtained on 
multivariate analysis.
The patients were followed up for 2.1 to 86.1 months, 
with a median follow-up duration of 21.5 months. The me-
dian survival time for all patients was 19.1 months (range, 
2.1–86.1 mo) when calculated from the diagnosis of isolated 
MS, and 3.6 months (range, 0.3–74.4 mo) from the diagnosis 
of AML (Table 1). The median OS time was longer in the 
LS group (21.5 mo) than in the S group (8.9 mo). Furthermore, 
the median PFS time was longer in the LS group (13.4 mo) 
than in the S group (2.6 mo). Three patients (33.3%) died 
of infections; however, for these patients, treatment-related 
mortality was not involved (Table 3).
DISCUSSION
In this study, we have described the overall clinical charac-
teristics of patients with isolated MS treated in our hospital. 
MS is a rare myeloid neoplasm that is composed of immature 
cells of the myeloid series and occurs in very different clinical 
settings. In particular, isolated MS is likely underdiagnosed, 
and thus, an accurate prevalence rate is difficult to determine. 
It has been estimated to affect 2 out of 1,000,000 adults 
and 0.7 out of 1,000,000 children [8]. The age-adjusted in-
cidence rate of isolated MS is 0.9% with a median age of 
59 years [9]. The cases described in this study, which dis-
played MS alone without evidence of AML, account for 
1.8% of all AML patients diagnosed in our hospital from 
1994 to 2015. Isolated MS has been reported to occur most 
often in men at the median age of 56 years (range, 1 mo 
–89 yr) [10]. The male gender predominance (55.6%) of 
our study population is similar, but our median age of 38 
years (range, 24–69 yr) is lower than that of previous studies.
A review of previous studies revealed the high misdiagnosis 
rate of isolated MS. According to Neiman et al. [11], an 
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accurate initial diagnosis was made in only 27 (44%) of 
61 patients. Of the remaining 34 patients, 31 were initially 
misdiagnosed with malignant lymphoma, 1 with malignant 
histiocytosis, 1 with synovial sarcoma, and another with 
Ewing’s tumor. Because isolated MS frequently exhibits fea-
tures mimicking a lymphomatous cell proliferation without 
definite morphologic evidence of granulocytic differ-
entiation, diagnostic differentiation from malignant lympho-
ma is very difficult [8, 11]. Because of these limitations of 
morphological diagnosis, immunohistochemical analysis is 
necessary during pathological assessment of specimens to 
differentiate MS from lymphomas or non-hematopoietic 
tumors. It is also important to determine whether naphthol 
AS-D chloroacetate esterase staining is negative to show 
the immature nature of the tumor cells [12].
In this study, immunohistochemical staining for myeloid 
markers, such as MPO, lysozymes, LCA, and CD68, was 
performed. Cell surface markers including CD4, CD30, CD34, 
TdT, and glycophorin A are also useful for diagnosis of MS 
[1]. Among the various markers, MPO, lysozyme, and CD68 
are the most sensitive and essential markers for myeloid 
differentiation [13]. In our patients, 1 case was initially diag-
nosed as extranodal NK/T-cell lymphoma, but the final diag-
nosis was corrected to MS through the addition of im-
munohistochemical analyses. Therefore, the use of multiple 
diagnostic modalities, including histochemical and im-
munoperoxidase stains, conventional and FISH cytogenetics, 
and flow cytometry, can support the accurate diagnosis of 
isolated MS.
In general, prior to the confirmative pathologic diagnosis 
through biopsy, various imaging modalities such as CT, MRI, 
or PET should be performed for the differential diagnosis, 
and imaging modalities have to be used to evaluate the extent 
of the disease after diagnosis of isolated MS. Imaging studies 
for extramedullary masses may be helpful to differentiate 
MS, lymphoma, metastasis, extramedullary hematopoiesis, 
and neurogenic tumors. The characteristic imaging findings 
of extramedullary masses at various sites and diffuse abnormal 
BM signal intensity help in the diagnosis of MS in association 
with leukemia. In previous studies, MS in soft tissues were 
reported to yield iso-dense or hyper-dense signals relative 
to brain or muscle on unenhanced CT, hypo-intense or iso-in-
tense signals on T1-weighted MRI, and heterogeneously 
iso-intense or hyper-intense signals on T2-weighted MRI, 
and were also known to homogeneously enhance after in-
jection of contrast medium [14-17].
In our study, the imaging characteristics on CT and MRI 
for MS lesions were fairly consistant. Spinal epidural MS 
and orbital MS were largely iso-intense on T1-weighted MRI 
and mildly hyper-intense to muscle on T2-weighted MRI. 
Other soft tissue MS masses, such as anterior mediastinum, 
small bowel, and submandibular gland, were largely 
iso-dense to muscle on CT. Because of its excellent soft tissue 
contrast, MRI is especially useful for the diagnosis of MS. 
Additionally, given the poor prognosis, an early and exact 
diagnosis of MS with MRI evaluation will facilitate appro-
priate treatment and disease control, preferably before the 
development of systemic leukemia. Therefore, MS should 
be considered in the differential diagnosis of new, mildly 
T2-hyper-intense, homogeneously enhancing soft tissue 
masses, especially in patients with a history of hematologic 
disease. However, the clinical usefulness of PET or PET-CT 
scans in diagnosing or differentially diagnosing MS has to 
be further validated.
MS can occur in any organ or tissue in the body, and 
the most common sites reported were bone, LN, and skin 
[18]. The head and neck area, anterior mediastinum, and 
small intestine, especially the jejunum, were more frequently 
involved in our patients, as compared with previous reports. 
Our study showed that the head and neck area tended to 
correlate with the evolution to AML more so than other 
sites (75% vs. 25%), but the number of involved lesions 
in isolated MS was not significantly related to the eventual 
evolution to AML. These data suggest that the initially in-
volved site, rather than the number of lesions, might be 
more important when considering the treatment strategy, 
and isolated MS occurring in the head and neck area espe-
cially must be followed more carefully.
Cytogenetic evaluation is important to classify the disease 
and to predict the outcome of myeloid neoplasms, especially 
AML. Similar to AML, cases of MS may harbor chromosomal 
abnormalities with prognostic significance [19]. Previous 
studies showed that about half of patients (55%) showed 
various cytogenetic abnormalities, such as monosomy 7, tris-
omy 8, trisomy 4, mixed lineage leukemia (MLL) rearrange-
ment, inv(16), monosomy 16, 16q-, 5q-, 20q-, and trisomy 
11 [10], with the rest having a normal karyotype. However, 
Pileri et al. [3] found a normal karyotype in 13 cases (46.4%) 
and Kaygusuz et al. [4] reported no cytogenetic abnormalities 
in 6 cases (54.5%). Breccia et al. [8] also reported that most 
patients (83.3%) showed a normal karyotype and only 2 
patients in their study (16.7%) revealed chromosomal abnor-
malities such as 47, XX, +13 and del(20). In our study, 6 
patients (66.7%) who underwent BM cytogenetic evaluation 
at the time of diagnosis of MS had a normal karyotype, 
but a normal karyotype in these patients did not appear 
to be correlated with a favorable outcome. Three patients 
(33.3%) could not have their karyotype evaluated owing 
to the failure of metaphasic cell cultivation. Performing cyto-
genetic examination for MS can be difficult if there is no 
BM involvement, possibly because of the relatively lower 
percentage of blasts in the BM. Despite the discrepancies 
between our data and those from previous literature, isolated 
MS should always be considered for the possibility of evolving 
into AML [8]. To validate the clinical significance of cytoge-
netic abnormalities in the pathogenesis or prognosis of MS, 
further studies with a larger number of patients are necessary.
Because it is similar to the plasmacytoma in plasma cell 
disorder, MS has been generally thought of as an antecedent 
disease entity able to evolve into AML; thus, treatment strat-
egies have been mainly focused on inducing a CR to prevent 
evolution to AML. In fact, if isolated MS is left untreated, 
it commonly evolves into AML within 1 year [20]. Unfor-
tunately, the optimal treatment for isolated MS has not yet 
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been clearly defined, in part because of the varied clinical 
presentations. Previous studies have suggested that the use 
of AML-like intensive chemotherapy in patients with iso-
lated MS has similar results to those with AML. Neiman 
et al. [11] reported that 26 (81%) of 32 patients who under-
went surgical resection or local radiotherapy progressed to 
AML within 11 months. On the contrary, 25 (58%) of 42 
patients administered chemotherapy remained in the 
non-leukemic stage for more than 11 months, and 8 (19%) 
did so for more than 2 years. Byrd et al. [21] reported similar 
results (mean, 10.5 mo) in patients not receiving 
chemotherapy. Meis et al. [22] also reported that 4 (25%) 
of 16 patients who received chemotherapy did not develop 
AML during a follow-up period of 3.5–16 years after diagnosis 
of MS. Interestingly, in our study, 2 patients (22.2%) who 
had undergone only local treatment, such as surgery and/or 
local radiotherapy, did not evolve to AML (Table 3). The 
CR durations of these patients were 1.8 months and 83.9 
months, respectively. These patients were characterized by 
solitary lesion involvement in the jejunum and L2 vertebral 
body at the time of diagnosis of isolated MS, unlike other 
patients in the LS group (Table 4). In contrast, tumors in 
4 patients (44.4%) who received systemic chemotherapy 
treatment had evolved to AML within a median time of 
13.4 months. Local treatment, such as surgery or radio-
therapy, might play an important role in controlling primary 
disease and relieving symptoms without significant toxicity 
and additional risk of evolution into AML [23, 24].
Although the role of radiotherapy is less clear, it can 
be considered as one of the treatment options in isolated 
MS [18]. Wong et al. [25] and Vassiliou et al. [26] reported 
similar cases of chemotherapy-resistant, isolated mediastinal 
MS who achieved a CR following additional radiotherapy. 
In our study, 1 patient with no response to chemotherapy 
alone and who underwent radiotherapy had no evidence 
of disease at follow-up. Tsimberidou et al. [7] reported a 
review of 20 cases of non-leukemic MS from the MD 
Anderson Cancer Center in which combination treatment 
with chemotherapy and radiotherapy resulted in better sur-
vival than chemotherapy alone. Although there were a lim-
ited number of patients in our study, our results suggest 
that combined systemic and local treatment for selected pa-
tients with isolated MS might be a better treatment strategy 
to achieve a CR, and to possibly cure the disease, as compared 
with chemotherapy alone.
More aggressive modalities such as allogeneic HSCT are 
alternative strategies for isolated MS. In previous studies, 
the mean disease-free survival time of 12 patients who re-
ceived allogeneic or autologous HSCT was reported to be 
27.3 months (12–48 mo) [27-29]. Our patient underwent 
allogeneic HSCT from a human leukocyte antigen (HLA)- 
matched sibling donor, in addition to surgery and intensive 
chemotherapy, and remains disease-free after 18 months. 
Because the role of HSCT has been rarely evaluated in MS 
and its efficacy is still unclear, additional case studies are 
necessary to evaluate the significance of HSCT [2, 27].
In conclusion, isolated MS is a rare and unique entity 
of myeloid neoplasm and there have been no large pro-
spective randomized studies to determine optimal treatment 
or prognosis. Survival of patients with MS exceeds that of 
patients with AML, but remains poor. Therefore, we suggest 
that initially correct and rapid diagnosis using a multiple 
modalities approach and early initiation of intensive com-
bined treatment may be the optimal strategy to reduce the 
risk of isolated MS subsequently evolving into AML. To 
fully understand the characteristics of isolated MS, a larger 
number of patients in a multinational study are necessary 
to identify novel and selected treatments.
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